Free From Infectious Agents (e.g., Viruses Or Bacteria Removed Or Inactivated, Etc.) Patents (Class 424/176.1)
  • Patent number: 9994611
    Abstract: Methods for the improved purification of antibodies and other proteins from protein preparations including the steps of conditioning the protein preparation by contacting it with multivalent organic ions, then applying the conditioned preparation to an adsorptive chromatography medium.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: June 12, 2018
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Peter Stanley Gagnon, Tze Yang Lee
  • Patent number: 9920120
    Abstract: Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: March 20, 2018
    Assignee: Genentech, Inc.
    Inventors: X. Christopher Yu, Susan C. Fisher, Ailen M. Sanchez, Martin Vanderlaan
  • Patent number: 9718856
    Abstract: The present invention relates to a method for preparing a concentrate of polyvalent immunoglobulins with view to therapeutic use, from an initial solution of blood plasma or a plasma fraction enriched with immunoglobulins, comprising the steps for removing the protein contaminants by precipitation with caprylic acid in order to obtain a solution free of proteases, and for separating by chromatography on a fluidized bed the solution free of proteases, said method allowing a concentrate of human polyvalent immunoglobulins with a yield of more than 4.5 g of immunoglobulins per liter of blood plasma applied to be obtained.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: August 1, 2017
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Abdessatar Chtourou, Damien Bataille, Georges Michaux
  • Patent number: 9556261
    Abstract: The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A?, anti-RAGE, and anti-?-synuclein antibodies), are also provided.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 31, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Lucia Gnauer, Harald Arno Butterweck, Theresa Bauer, Alfred Weber, Wolfgang Teschner, Hans-Peter Schwarz
  • Patent number: 9468674
    Abstract: Described herein are methods of preventing and/or treating inflammation in a barrier surface structure in an individual in need thereof by orally administering to the individual an anti-inflammatory amount of secretory IgA.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: October 18, 2016
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Mark E. Cook, Jordan Marshall Sand, Lisa Ann Krugner-Higby, James Mukasa Ntambi
  • Patent number: 9274122
    Abstract: The invention relates to the development of in vitro assay systems that force the release of a water-soluble polymer, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins modified with a reversibly-linked water-soluble polymer. The invention includes methods for analyzing the release of the water-soluble polymer and measuring regained protein activity. The invention further includes methods appropriate for the quality control of proteins modified with releasable water-soluble polymers, including polymers like PEG and PSA.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: March 1, 2016
    Assignees: BAXALTA INCORPORATED, BAXALTA GMBH, NEKTAR THERAPEUTICS
    Inventors: Katalin Varadi, Gerald Schrenk, Hanspeter Rottensteiner, Peter Turecek, Alfred Weber, Heinz Anderle, Sean M. Culbertson, Zhihao Fang, Harold Zappe, Ping Zhang, Mary J. Bossard
  • Publication number: 20140199262
    Abstract: The present invention provides a method for manufacturing a virus-free protein drug, comprising (a) a filtration step of filtering a virus-containing protein solution through a small-pore size virus removal membrane to obtain a virus-free protein solution, the filtration step (a) comprising (q) a low-pressure filtration step of filtering the solution through the small-pore size virus removal membrane at a filtration pressure of 0.30 kgf/cm2 or lower to obtain the virus-free protein solution, wherein the solution prior to filtration in the low-pressure filtration step (q) has a pH (X) and a salt ionic strength (Y (mM)) that satisfy the following equations 1 and 5: 0?Y?150X?590 (Equation 1) and 3.5?X?8.0 (Equation 5) or the following equations 4 and 5: Y=0 (Equation 4) and 3.5?X?8.0 (Equation 5).
    Type: Application
    Filed: June 22, 2012
    Publication date: July 17, 2014
    Applicant: ASAHI KASEI MEDICAL CO., LTD.
    Inventors: Tomoko Hongo, Hirohisa Hayashida
  • Patent number: 8771695
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: July 8, 2014
    Assignees: U3 Pharma GmbH, Amgen, Inc.
    Inventors: Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges
  • Patent number: 8470328
    Abstract: The present invention provides a method of purifying an antibody by protein A affinity chromatography. More specifically, the present invention provides a technique relating to an elution buffer solution which provides a good antibody recovery rate without denaturation.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: June 25, 2013
    Assignee: Ajinomoto Co., Inc.
    Inventors: Ryosuke Yumioka, Daisuke Ejima, Tsutomu Arakawa
  • Patent number: 8435527
    Abstract: The present invention provides a method of purifying an antibody by protein A affinity chromatography. More specifically, the present invention provides a technique relating to an elution buffer solution which provides a good antibody recovery rate without denaturation.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: May 7, 2013
    Assignee: Ajinomoto Co., Inc.
    Inventors: Ryosuke Yumioka, Daisuke Ejima, Tsutomu Arakawa
  • Publication number: 20130052208
    Abstract: A process is provided for the preparation of an immunoglobulin composition from a plasma fraction having immunoglobulins, and antibody preparations prepared utilizing the process.
    Type: Application
    Filed: October 19, 2012
    Publication date: February 28, 2013
    Applicant: BIOTEST AG
    Inventor: BIOTEST AG
  • Patent number: 8350013
    Abstract: The invention relates to methods for isolating a product and/or reducing turbidity and/or impurities from a load fluid comprising the product and one or more impurities by passing the load fluid through a medium, followed by at least one wash solution comprising arginine, and collecting the product using an elution solution. The invention further relates to a product prepared using a method as described herein.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: January 8, 2013
    Assignee: Wyeth LLC
    Inventor: Shujun Sun
  • Patent number: 8293242
    Abstract: The instant invention provides novel and effective methods of isolating alpha-1-antitrypsin from cryo-poor plasma and formulating it into therapeutic products. This invention achieves higher yields and a superior quality of alpha-1-antitrypsin. Alpha-1-antitrypsin is isolated from cryo-poor plasma, using one or more salts selected from a group comprising sodium citrate, sodium acetate, sodium gluconate, ammonium sulfate, sodium chloride, sodium sulfate and ammonium chloride in two fractionation steps, followed by diafiltration to remove those salts employed.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: October 23, 2012
    Assignee: Plasma Technologies, LLC
    Inventors: Gene Zurlo, Dennis Curtin, Allan Louderback
  • Patent number: 8231876
    Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: July 31, 2012
    Assignee: Abbott Biotechnology Ltd.
    Inventors: Min M. Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
  • Patent number: 8188242
    Abstract: Methods, kits and apparatuses for chromatography purification of antibodies are provided. In some embodiments, antibodies are purified by mixed mode chromatography that does not comprise hydroxyapatite (HT) or fluorapatite (FT). The mixed mode chromatography step is then followed by a HT/FT chromatography step.
    Type: Grant
    Filed: April 7, 2009
    Date of Patent: May 29, 2012
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Peter S. Gagnon, Hong Chen, Russ Frost
  • Patent number: 8163886
    Abstract: The present invention relates to a selectively soluble polymer capable of binding to one or more constituents in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and is rendered insoluble and precipitates out of solution upon a change in the process conditions. While in its solubilized state, the polymer is capable of binding to a selected entity within the stream such as impurities (DNA, RNA, host cell protein, endotoxins, etc) in a cell broth and remains capable of binding to that entity even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered and further processed.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: April 24, 2012
    Assignee: EMD Millipore Corporation
    Inventor: Wilson Moya
  • Patent number: 8124397
    Abstract: The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided.
    Type: Grant
    Filed: August 7, 2006
    Date of Patent: February 28, 2012
    Assignee: Oregon Health & Science University
    Inventors: Mark K. Slifka, Shirley V. Carter, Erika Hammarlund, Paul Yoshihara
  • Patent number: 8084032
    Abstract: The present invention provides a method of purifying an antibody by protein A affinity chromatography. More specifically, the present invention provides a technique relating to an elution buffer solution which provides a good antibody recovery rate without denaturation.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: December 27, 2011
    Assignee: Ajinomoto Co., Inc.
    Inventors: Ryosuke Yumioka, Daisuke Ejima, Tsutomu Arakawa
  • Patent number: 8017740
    Abstract: This invention relates to the use of mixed mode chromatography for purification of at least one intact non-aggregated antibody from a mixture containing intact non-aggregated antibodies and undesirable materials, including fragmented or aggregated antibodies, host cell proteins, DNA, endotoxin, and/or virus. This invention further relates to the integration of such a method into a multi-step procedure with other fractionation methods for purification of antibodies suitable for in vivo applications.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: September 13, 2011
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Peter S. Gagnon
  • Publication number: 20110097344
    Abstract: The present invention provides compositions and methods useful in the diagnosis and treatment of autoimmunity-related disorders, including cancers and other disorders involving angiogenesis, as well as non-cancer disorders involving a dysfunction in the immune system. In some embodiments, the invention described a plasma assay. In other embodiments, urine assay. In certain other embodiments, the invention provides therapeutic methods comprising removing toxic autoantibodies from the circulation of a patient, e.g., via plasmapheresis, and subsequently infusing the patient with one or more immunoglobulins or immunoglobulin complexes to restore the immune system of the patient to a baseline status whereby the patient's restored immune system either eliminates the source of the disorder (e.g., in the case of cancers) or no longer causes the disease or disorder (e.g., in the case of autoimmune disorders such as multiple sclerosis, psoriasis, latent autoimmune type 1 diabetes in adults (LADA) and the like).
    Type: Application
    Filed: October 22, 2010
    Publication date: April 28, 2011
    Applicant: EIGER HEALTH PARTNERS, LLC.
    Inventors: Oleg DARASHKEVICH, Stuart Juckett
  • Patent number: 7879331
    Abstract: An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs sodium citrate in two initial fractionation steps, followed by diafiltration to remove sodium citrate.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: February 1, 2011
    Assignee: Plasma Technologies, LLC
    Inventors: Eugene J. Zurlo, Dennis D. Curtin, Allan L. Louderback
  • Patent number: 7879332
    Abstract: An efficacious large-scale alcohol-free plasma fractionation production process which produces a high-yielding, non-denatured, double viral-inactivated intravenous human immune gamma globulin (IgG) product. The process employs one or more salts from a group of salts comprising sodium citrate, sodium acetate, sodium gluconate, ammonium sulfate, sodium chloride, sodium sulfate and ammonium chloride in two initial fractionation steps, followed by diafiltration to remove those salts employed. A process which employs alcohol via the process of the disclosed inventive method is also disclosed.
    Type: Grant
    Filed: February 21, 2006
    Date of Patent: February 1, 2011
    Assignee: Plasma Technologies, LLC
    Inventors: Gene Zurlo, Dennis Curtin, Allan L. Louderback
  • Patent number: 7863426
    Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: January 4, 2011
    Assignee: Abbott Biotechnology Ltd.
    Inventors: Min Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
  • Patent number: 7834162
    Abstract: Various system and method embodiments of the present invention are directed to separating target molecules from complex solutions by affinity column chromatography using organic-solvent-containing eluants. In one embodiment of the present invention, an eluant containing an organic-solvent is used, at a first pH, to remove non-target solutes and suspended entities from an affinity chromatography column. The pH of the eluant is then changed to a second pH, and the organic-solvent-containing eluant is used to elute target molecules from the affinity column chromatography.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: November 16, 2010
    Assignee: Amgen Inc.
    Inventor: Joe Xin Hua Zhou
  • Patent number: 7714111
    Abstract: The invention relates to methods for isolating a product and/or reducing turbidity and/or impurities from a load fluid comprising the product and one or more impurities by passing the load fluid through a medium, followed by at least one wash solution comprising an arginine derivative, and collecting the product using an elution solution. The invention further relates to a product prepared using a method as described herein.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: May 11, 2010
    Assignee: Wyeth LLC
    Inventors: Shujun Sun, Christopher Gallo
  • Patent number: 7691980
    Abstract: This invention relates to the use of mixed mode chromatography for purification of at least one intact non-aggregated antibody from a mixture containing intact non-aggregated antibodies and undesirable materials, including fragmented or aggregated antibodies, host cell proteins, DNA, endotoxin, and/or virus. This invention further relates to the integration of such a method into a multi-step procedure with other fractionation methods for purification of antibodies suitable for in vivo applications.
    Type: Grant
    Filed: January 7, 2008
    Date of Patent: April 6, 2010
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Peter S. Gagnon
  • Patent number: 7662930
    Abstract: Various embodiments of the present invention are directed to multi-step systems and methods for target-molecule purification that employ column-chromatography-based and/or membrane-filtration-based polishing steps. In one described embodiment of the present invention, a target-protein-containing eluate having a high residual salt concentration is collected from a first chromatography column prepared with an affinity-chromatography resin, loaded onto a second chromatography column prepared with a cation-exchange resin, and eluted from the second cation-exchange column using a buffer in which a time-dependent pH gradient is established. In another described embodiment of the present invention, a partially purified target-protein-containing eluate is collected from a chromatography column and further purified by passing the target-protein-containing eluate through a salt-tolerant anion exchanger.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: February 16, 2010
    Assignee: AMGEN Inc.
    Inventor: Joe Xin Hua Zhou
  • Patent number: 7655233
    Abstract: The solvent-detergent (S/D) process is used to inactivate enveloped viruses in plasma products. While concentrations of 1.0% detergent and 0.3% tri-n-butyl phosphate solvent have been considered necessary for robust removal of viral activity, we show the effectiveness of solvent-detergent treatment after fractionation and nanofiltration of an immune gamma globulin preparation, which required significantly reduced concentrations of solvent and detergent. Reduced levels of solvent and detergent lead to greater efficiencies in their removal post-inactivation with the potential for greater yields and decreased processing costs.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: February 2, 2010
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventors: Robert W. Van Holten, Stephen M. Autenrieth
  • Patent number: 7635722
    Abstract: An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: December 22, 2009
    Assignee: Saint Jude Pharmaceuticals, Inc.
    Inventors: Nicholas Bachynsky, Woodie Roy
  • Patent number: 7569643
    Abstract: The present invention relates to novel polymeric compositions based upon An(BCB)An polyester/polyether multi-blocks. Compositions according to the present invention exhibit unexpectedly exceptional reverse thermal gellation properties and in certain cases, relatively low viscosities at approximately room temperature and extremely high viscosities at temperatures above room temperature (preferably at approximately physiological or body temperature, i.e., within a temperature range of about 32-40° C.). Compositions according to the present invention may be used advantageously in applications which make use of their reverse thermal gellation properties. Preferred applications for use of the present compositions include, for example, medical applications which make advantageous use of the inherent composition characteristic of being of relatively low viscosity at room temperature and much higher viscosity at elevated temperatures, especially body temperature.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: August 4, 2009
    Assignee: Synthemed, Inc.
    Inventors: Daniel Cohn, Avraham Levi
  • Patent number: 7553938
    Abstract: A method of preparing a purified, virus inactivated and virus safe antibody preparation from a starting solution comprising antibodies and contaminants, the method comprising the steps of: (a) adjusting the pH of the starting solution to about 4.6 to about 4.95 in particular to about 4.8 to about 4.95 to produce an intermediate solution; (b) adding caprylate and/or heptanoate ions to the intermediate solution and maintaining the pH at about 4.6 to about 4.95 in particular pH at about 4.8 to about 4.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: June 30, 2009
    Assignee: Octapharma AG
    Inventors: Andrea Buchacher, Günther Iberer, Jürgen Römisch
  • Patent number: 7476722
    Abstract: A method is provided for separating a protein from one or more other proteins using hydroxyapatite chromatography in which the protein does not bind to hydroxyapatite but the other protein(s) does. In some embodiments, a second protein affixed to a solid support has been used previously to purify the protein by affinity chromatography, and small amounts of the second protein are introduced in the sample during this process. The protein being purified can comprise at least one constant antibody immunoglobulin domain. The second protein can bind to proteins comprising such a domain.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: January 13, 2009
    Assignee: Immunex Corporation
    Inventors: Ganesh Vedantham, Clayton Brooks, III, Joanne M Reeder, Andrew M Goetze
  • Patent number: 7452539
    Abstract: Methods for stabilizing polypeptides, such as anti-HER2 antibodies, which have been exposed to urea.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: November 18, 2008
    Assignee: Genentech, Inc.
    Inventors: Jefferson C. Emery, Paul J. McDonald, Rhona M. O'Leary
  • Publication number: 20080145371
    Abstract: A composition for treating a subject is provided. The composition includes dimeric or polymeric secretory IgA therapeutic. Formulating agents are mixed with the dimeric or polymeric secretory IgA to yield a dosing form of a capsule, tablet, and a suppository. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of dimeric or polymeric IgA with secretory component to form a dimeric or polymeric secretory IgA therapeutic. The dimeric or polymeric secretory IgA therapeutic is then mixed with formulating agents to create a capsule, tablet, or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.
    Type: Application
    Filed: August 16, 2007
    Publication date: June 19, 2008
    Inventor: Michael R. Simon
  • Patent number: 7368542
    Abstract: The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can be recovered from blood or blood products or extracts by oxidizing the protein to change its binding specificity.
    Type: Grant
    Filed: June 9, 2004
    Date of Patent: May 6, 2008
    Assignee: Redox-Reactive Reagents LLC
    Inventor: John A. McIntyre
  • Patent number: 7339037
    Abstract: The invention provides a method of inhibiting prophylactically or therapeutically an influenza viral infection in a host. The method comprises instilling into or onto a host a cell producing an antiviral protein, antiviral peptide, or antiviral conjugate comprising at least nine contiguous amino acids of SEQ ID NO: 2, wherein the at least nine contiguous amino acids are nonglycosylated and have antiviral activity, whereupon the influenza viral infection is inhibited.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: March 4, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Michael R. Boyd, Barry R. O'Keefe, Toshiyuki Mori, Angela M. Gronenborn
  • Patent number: 7252799
    Abstract: Methods are disclosed for sterilizing preparations containing albumin to reduce the level of one or more active biological contaminants or pathogens therein, such as viruses, bacteria (including inter- and intracellular bacteria, such as mycoplasmas, ureaplasmas, nanobacteria, chlamydia, rickettsias), yeasts, molds, fungi, prions or similar agents responsible, alone or in combination, for TSEs and/or single or multicellular parasites. These methods involve sterilizing preparations containing albumin, such as plasma protein fractions, with irradiation.
    Type: Grant
    Filed: August 31, 2001
    Date of Patent: August 7, 2007
    Assignee: Clearant, Inc.
    Inventors: Shirley I. Miekka, Wilson Burgess, William N. Drohan, Martin J. Macphee, Randall S. Kent, David M. Mann, Yuri Griko
  • Patent number: 7241592
    Abstract: Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to both Staphylococcus aureus and Staphylococcus epidermidis bacteria and which can thus be used in the prevention and treatment of infections caused by both of these types of bacteria. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the proteins are advantageous because they are cross-reactive and may thus be administered to patients so as to reduce or prevent severe infection by staphylococcal bacteria of more than one species.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: July 10, 2007
    Assignees: Universita Degli Studi di Pavia, The Texas A&M University System, Inhibitex, Inc.
    Inventors: Magnus Hook, Yi Xu, Pietro Speziale, Livia Visal, Fabrizia Casolini, Joseph M. Patti, Pratiksha Patel, Paul Domanski
  • Patent number: 7186410
    Abstract: The invention concerns a method for preparing human immunoglobulin concentrates for therapeutic use, from plasma or a plasma fraction. The method comprises pre-purification and a single anion-exchange chromatography carried out at alkaline pH, thereby enabling the immunoglobulins to be retained on the chromatographic support and fractionated. The method enables to obtain IgG, IgA and IgM concentrates.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: March 6, 2007
    Assignee: Laboratoiore Francais du Fractionnement et des Biotechnologies
    Inventors: Abdessatar Sami Chtourou, Philippe Paolantonacci, Roland Schmitthaeusler, Jacky Lirochon
  • Patent number: 7138120
    Abstract: The present invention relates to a process for purifying immunoglobulin G from a crude immunoglobulin-containing plasma protein fraction. Said process includes a number of steps of which the anion exchange chromatography and the cation exchange chromatography are preferably connected in series. An acetate buffer having a pH of about 5.0-6.0 and having a molarity of about 5-25 mM is preferably used throughout the purification process. The invention further comprises an immunoglobulin product which is obtainable by this process. The invention also relates to an immunoglobulin product which has a purity of more than 98%, has a content of IgG monomers and dimers of more than 98.5%, has a content of IgA less than 4 mg of IgA/l, and contains less than 0.5% polymers and aggregates. Said product does not comprise detergent, PEG or albumin as a stabilizer. The product is stable, virus-safe, liquid and ready for instant intravenous administration.
    Type: Grant
    Filed: July 10, 2001
    Date of Patent: November 21, 2006
    Assignee: Statens Serum Institut
    Inventors: Inga Laursen, Børge Teisner
  • Patent number: 7125552
    Abstract: The method for immune serum globulin purification relates to the purification of immune globulins from blood plasma with a high degree of efficiency and a high rate of recovery. The immune globulin source is Cohn's fraction I+II+III or II+III prepared from plasma or plasma intermediates by precipitation of the paste at pH 6.7 to 6.8 in the presence of 20% ethanol and 80% purified water. A glycine extraction is followed by an anion exchange chromatography column step to achieve a significantly high yield and high purity of the concentrated protein.
    Type: Grant
    Filed: May 13, 2005
    Date of Patent: October 24, 2006
    Assignee: Hemacare Corporation
    Inventors: Joshua Levy, Fred Rothstein, Bahman Shimiaei
  • Patent number: 7122641
    Abstract: A method is provided for separating a protein from one or more other proteins using hydroxyapatite chromatography in which the protein does not bind to hydroxyapatite but the other protein(s) does. In some embodiments, a second protein affixed to a solid support has been used previously to purify the protein by affinity chromatography, and small amounts of the second protein are introduced in the sample during this process. The protein being purified can comprise at least one constant antibody immunoglobulin domain. The second protein can bind to proteins comprising such a domain.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: October 17, 2006
    Assignee: Immunex Corporation
    Inventors: Ganesh Vedantham, Clayton A. Brooks, III, Joanne M. Reeder, Andrew M. Goetze
  • Patent number: 7060268
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: June 13, 2006
    Assignee: Genentech, Inc.
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • Patent number: 7041798
    Abstract: The invention relates to the fractionation of plasma or serum into at least one albumin fraction and one immunoglobulin fraction by hydrophobic interaction chromatography. The fractionation is carried out using an incremental salt gradient, especially an ammonium sulfate buffer. The invention also relates to preparations obtained by using said method and to their use.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: May 9, 2006
    Assignee: Biotest Pharma GmbH
    Inventors: Norbert Kothe, Dieter Rudnick, Michael Kloft
  • Patent number: 6893639
    Abstract: The method for immune serum globulin purification relates to the purification of immune globulins from blood plasma with a high degree of efficiency and a high rate of recovery. The immune globulin source is Cohn's fraction I+II+III or II+III prepared from plasma or plasma intermediates by precipitation of the paste at pH 5.7 to 5.8 in the presence of 20% ethanol and 80% purified water. A glycine extraction is followed by an anion exchange chromatography column step to achieve a significantly high yield and high purity of the concentrated protein.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: May 17, 2005
    Assignee: Hemacare Corporation
    Inventors: Joshua Levy, Fred Rothstein, Bahman Shimiaei
  • Patent number: 6875848
    Abstract: The gammaglobulin is extracted from a fraction isolated by fractionation with ethanol in the presence of a carbohydrate, and after reducing the content of contaminants with PEG, it is applied to an anionic resin exchange column, an effluent being obtained in which the PEG content is subsequently reduced by ultrafiltration and which is concentrated in order to carry out sequentially an optional treatment at an acid pH and at least one of the following steps of viral inactivation, consisting of pasteurisation and a treatment with solvent/detergent, the product afterwards being precipitated and washed with PEG in order to eliminate any chemical viral inactivation reagents and then, by solubilisation and change of pH, the protein contaminants, and finally purified by ultrafiltration to reduce the volume and the PEG content, then carrying out an optional virus filtration and subsequent concentration.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: April 5, 2005
    Assignee: Probitas Pharma, S.A.
    Inventors: Pere Ristol Debart, Francisco Rabaneda Gimenez, Ma Teresa Lopez Hernandez
  • Patent number: 6875432
    Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
    Type: Grant
    Filed: October 4, 2001
    Date of Patent: April 5, 2005
    Assignees: Genentech, Inc., Novartis AG
    Inventors: Jun Liu, Steven J. Shire
  • Patent number: 6870012
    Abstract: A composition exhibiting reverse thermal gellation properties comprises a block polymer having the structure: {[An(BCB)An]}m wherein A is a polyester unit, B is a poly(ethylene oxide) unit, C is a poly(propylene oxide) unit, E is a chain extender unit, n=0-20, and m is greater than 2. The ethylene oxide:propylene oxide ratio ranges from about 0.2:1 to about 40:1. The composition has a final viscosity at a final temperature of more than twice the initial viscosity at an initial temperature wherein the final temperature is at least 10° C. higher than the initial temperature. The composition is combined with either a cellular material for tissue engineering, a cellular material for effecting repair or healing in a patient, or a bioactive agent.
    Type: Grant
    Filed: April 24, 2003
    Date of Patent: March 22, 2005
    Assignee: Life Medical Sciences, Inc.
    Inventors: Daniel Cohn, Avraham Levi
  • Patent number: 6773600
    Abstract: The invention relates to the field of protein purification and the recovery of large proteinaceous material through small, nanometer sized, pore exclusion filters for removal of contaminants such as viral pathogens.
    Type: Grant
    Filed: June 4, 2003
    Date of Patent: August 10, 2004
    Assignee: Cantocor, Inc.
    Inventors: Barry P. Rosenblatt, Richard C. Siegel
  • Patent number: 6696060
    Abstract: Methods are disclosed for sterilizing preparation of monoclonal immunoglobulins to reduce the level of active biological contaminants such as viruses, bacteria, yeasts, molds, mycoplasmas, prions and parasites.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: February 24, 2004
    Assignee: Clearant, Inc.
    Inventors: Teri Grieb, Wilson H. Burgess, William N. Drohan, Ren-Yo Forng, Martin J. MacPhee, David M. Mann, Anna McBain